Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Polyphenon E to Treat External Genital Warts

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age \>= 18 years at the time of enrollment~* Clinical diagnosis of external genital warts (located genital, inguinal, perineal or perianal)~* At least 2, but no more than 30 external genital warts~* A total wart area between 12 and 600mm²~* Negative pregnancy test and willingness to use effective contraception (for women of child-bearing potential)~* For partners of male patients who are of child-bearing potential: use of effective contraception during the treatment period~* Written informed consent~* Ability to comply with the requirements of the study~Exclusion Criteria:~* Participation in an investigational trail within 30 days prior to enrollment~* Previous participation in a trial investigating Polyphenon E in the treatment of external genital warts~* Treatment of external genital warts within 30 days prior to enrollment and for the whole study duration~* Systemic intake of virostatics within 30 days prior to enrollment and for the whole study duration~* Systemic intake of immunosuppressive or immunomodulatory medication within 30 days prior to enrollment and for the whole study duration~* Current infection with Herpes genitalis or history of Herpes genitalis infection within the last 3 month~* Any current and/or recurrent pathologically relevant genital infections other than genital warts~* Current known acute or chronic infection with HBV or HCV~* Known HIV infection~* Any current uncontrolled infection~* Organ allograft~* For female patients: pregnancy or lactation~* Known allergies against any of the ingredients of the treatments~* Any chronic or acute skin condition susceptible of interfering with the evaluation of the drug effect~* Any chronic condition susceptible, in the opinion of the investigator, of interfering with the conduct of the study~* Internal (vaginal or rectal) warts requiring treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).